Načítá se...
Bromocriptine improves glucose tolerance independent of circadian timing, prolactin, or the melanocortin-4 receptor
Bromocriptine, a dopamine D2 receptor agonist originally used for the treatment of hyperprolactinemia, is largely successful in reducing hyperglycemia and improving glucose tolerance in type 2 diabetics. However, the mechanism behind bromocriptine’s effect on glucose intolerance is unclear. Here, we...
Uloženo v:
| Vydáno v: | Am J Physiol Endocrinol Metab |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Physiological Society
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6985791/ https://ncbi.nlm.nih.gov/pubmed/31794265 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajpendo.00325.2019 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|